Schering-Plough’s NDA for Noxafil Oral Suspension (for use in preventing serious invasive fungal infections (IFIs) in high-risk patients) has been granted a six-month priority review by the FDA. Priority review designation is granted to drugs that, if approved, would be a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease. The company is seeking U.S. marketing approval of Noxafil for prophylaxis of serious invasive fungal infec...